+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 23 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness of Vagus Nerve Stimulation VNS Therapy as an additional treatment for people with treatment-resistant depression. The study compares active VNS treatment with a no stimulation control over a 12-month period to see if VNS can reduce depressive symptoms measured by several depression scales. This is a prospective, multi-center, randomized, controlled, and blinded trial involving subjects who have VNS devices implanted. Participants receive the VNS implant, and after at least two weeks, they are randomized to either have the device activated or not activated for the first 12 months. Those in the control group can receive stimulation after 12 months. After the initial 12-month randomized phase, all participants transition into an open-label, long-term study lasting about 5 years. New subjects may also enroll directly into this extension phase. During the trial, participants are assessed regularly using multiple depression rating scales and questionnaires to monitor changes in symptoms, response times, remission, and adverse events. Safety and quality of life measures are also tracked. The study includes thorough monitoring of depressive symptoms and overall functioning for up to 12 months post-randomization, followed by long-term observation for several years.

Age: 18Years +All GendersPhase Not Applicable
101 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of CREXONT, an extended-release capsule containing Carbidopa and Levodopa, in people with Parkinson disease PD under real-world conditions. This Phase 4 study aims to understand how well CREXONT works in reducing motor symptom fluctuations in participants who are already treated with stable oral Carbidopa-Levodopa regimens. Participants will receive CREXONT extended-release capsules orally, with doses guided by FDA-approved prescribing information. The capsules come in several strengths, and dosing will be adjusted individually to find the best balance between effectiveness and tolerability. The study includes an initial dosing based on prior oral medication and allows optimization throughout the study to meet each participants needs. During the study, participants will complete Parkinsons Disease diaries to track On and Off motor states, and researchers will measure changes in Good On time and Off time by Day 42 compared to baseline. Participants will attend study visits and may receive questionnaires and assessments to monitor their condition and treatment response. The study is open-label, meaning all participants receive CREXONT, and the total participation duration includes baseline and follow-up assessments through Day 42.

Age: 18Years +All GendersPhase 4
27 locations
E

Actively Recruiting

Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.

Age: 18Years +All GendersPhase 3
679 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tezepelumab, a biological drug, in adults aged 40 to 80 with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase 3, randomized, double-blind, placebo-controlled study includes participants who have experienced worsening COPD symptoms despite inhaled maintenance therapy. The study aims to reduce the rate of moderate or severe COPD exacerbations, which are episodes when symptoms worsen significantly. Participants will receive monthly subcutaneous injections of either one of two doses of tezepelumab or a matching placebo for a minimum of 52 weeks and up to 76 weeks. After the treatment period, there is a 12-week safety follow-up without treatment. The study compares tezepelumabs effects to placebo to evaluate its impact on lung function, COPD symptoms, and exacerbation frequency. Throughout the study, participants will undergo regular assessments including lung function tests, symptom questionnaires, and blood tests to monitor immune response and drug levels. Researchers will track COPD exacerbations and quality of life changes using tools like the St. Georges Respiratory Questionnaire and COPD Assessment Test. Safety will be monitored during and after treatment, with the entire participation lasting up to about 88 weeks including follow-up.

Age: 40Years - 80YearsAll GendersPhase 3
305 locations
O

Actively Recruiting

Researchers are observing Parkinsons disease in patients aged 45 to 75 who continue to have movement symptoms despite taking standard Parkinsons medications. The study aims to better understand how the disease changes over time in this group, the challenges faced by patients and their care partners, and how current treatments are working in real life. Parkinsons disease causes movement problems like tremors, stiffness, slow movements, and balance difficulties, as well as non-motor symptoms such as mood changes and sleep issues. This study fills gaps left by earlier research that did not track patients long enough or collect comprehensive data. Participants will continue receiving their usual care without any changes, as no investigational treatments are given. Data will be collected from December 2025 to December 2032 and may include questionnaires, medical records, blood samples, skin biopsies, digital movement tracking devices, and reports from care partners. Both patients and their primary care partners may participate in the study. During the study, researchers will collect various types of information such as medical history, medications, movement and non-movement symptoms, genetic data, and the burden of care including psychological and economic aspects. Assessments will be done through doctor interviews, patient diaries, medical records, and digital monitoring. Participants may be followed for up to 5 years to provide a detailed understanding of disease progression and treatment effects.

Age: 45Years - 75YearsAll Genders
27 locations
S

Actively Recruiting

Researchers are evaluating the use of apixaban compared to aspirin to prevent stroke or death in patients who have had a recent intracerebral hemorrhage ICH and also have atrial fibrillation AF. This phase III randomized, double-blinded trial aims to determine if apixaban is superior in preventing any type of stroke or death, as well as if it leads to better functional recovery measured by the modified Rankin Scale. The study will enroll 700 patients and follow them for 12 to 36 months to assess these outcomes. Participants will be randomly assigned to receive either apixaban or aspirin. Apixaban dosing is typically 5 mg twice daily, with a reduced dose of 2.5 mg twice daily for those meeting specific criteria such as older age, lower body weight, or certain medication use. Aspirin is given once daily at a dose of 81 mg. The study includes a treatment period after recent ICH, with careful monitoring for safety and efficacy. During the study, participants will undergo regular assessments including evaluation of stroke occurrence, death, and changes in functional status using the modified Rankin Scale. Safety and adherence will be monitored throughout the follow-up period, which ranges from 12 months up to 3 years. The research team will collect data to understand the benefits and risks of apixaban versus aspirin in this patient population.

Age: 18Years +All GendersPhase 3
187 locations
P

Actively Recruiting

This trial studies very low-risk and low-risk fusion-negative rhabdomyosarcoma, a type of soft tissue cancer, focusing on maintaining good outcomes while reducing therapy burden. It also evaluates how molecular risk classification can guide treatment and examines intensified therapy for tumors with specific DNA mutations. The study is a phase III clinical trial led by the Childrens Oncology Group. Participants receive one of several chemotherapy regimens based on their risk group and mutation status. Very low-risk patients get vincristine and dactinomycin every 21 days for 8 cycles. Low-risk patients receive vincristine, dactinomycin, and cyclophosphamide for 4 cycles, followed by vincristine and dactinomycin for 4 more cycles. Patients with specific mutations switch to an intensified regimen involving vincristine, dactinomycin, and cyclophosphamide for 12-13 cycles. Radiation therapy may be given during cycle 5 if needed. Throughout the study, participants undergo CT scans, MRI, bone scans, PET scans, and tumor biopsies for evaluation. Blood and tissue samples are collected at multiple points for future research. Researchers monitor failure-free survival and overall survival over several years, while also assessing the feasibility of central molecular risk testing. The total study duration and follow-up extend up to five years.

Age: 0 - 21YearsAll GendersPhase 3
181 locations
U

Actively Recruiting

This research aims to analyze data from the Fitbit wearable device to predict infections after surgery in children with complicated appendicitis. The study focuses on how this prediction affects clinical decision-making, time to first contact with healthcare, and postoperative healthcare use. The study involves children aged 3 to 18 who have undergone laparoscopic appendectomy for complicated appendicitis, with the goal of improving early infection detection and patient care. Participants will wear Fitbit devices that collect heart rate, physical activity, and sleep data in near-real time. Machine learning methods will be applied to this data to develop and validate an algorithm that detects postoperative infection. The study has two main parts first, developing and validating the infection prediction algorithm using Fitbit data second, assessing how access to real-time infection alerts influences clinicians decisions and healthcare use. This includes daily reports and alerts sent to surgeons for patients in the implementation phase. Throughout the study, Fitbit data and daily symptom diaries will be collected for 30 days from enrollment to monitor recovery. Researchers will analyze changes in physical activity, heart rate, sleep patterns, symptom reports, healthcare visits, and clinician decision-making. The study includes surveys and qualitative assessments to understand the impact of Fitbit data on care. Participants are monitored for postoperative infection and healthcare utilization during this period, supporting early detection and improved management.

Age: 3Years - 18YearsAll GendersPhase Not Applicable
4 locations

1-10 of 23

1